As a global pharmaceutical leader, we are doing all we can to protect the health of our employees, their families and our communities, while ensuring our medicines continue to reach patients who rely on them. With this in mind, we are taking a number of steps to address COVID-19 and to help minimize its transmission, including developing a plasma-derived therapy to treat high-risk COVID-19 patients. We are also strongly recommending that all employees work from home where possible, in alignment with their site and group requirements.
Coronavirus and Product Supply
Takeda’s strategy is to secure product supply continuity for patients through managing adequate levels of inventory and/or alternative suppliers for the production of our medicines. This strategy is generally applied across our global supply chain for key starting materials, excipients, raw materials, APIs, and finished products.
Based on current assessments of our global supply chain, we do not anticipate any potential supply disruption in the near-term due to the Coronavirus outbreak. Longer-term, it is not yet possible to predict precisely what the impact may be on individual products. We will continue to monitor the situation as it evolves and take all necessary actions in an effort to ensure supply continuity for the people we serve.